Skip to main content

Table 1 Patient characteristics

From: Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma

  No. %
Total patients enrolled 29 100
   Treated 27 93
Age, years   
   Median 49  
   Range 32–64  
Male gender 24 83
Zubrod performance status   
   0 7 24
   1 18 62
   2 4 14
Child-Pugh classification   
   A 29 100
Hepatitis virus serology   
   Hepatitis B 19 66
   Hepatitis C 0 0
Prior treatment(s)   
   Surgery 2 7
   Transarterial chemoembolization 16 55
Pretreatment alpha fetoprotein (AFP)   
   < 400 ng/mL 8 28
   400–10,000 ng/mL 14 48
   > 10,000 ng/mL 7 24
Pretreatment laboratory data, mean ± SD   
   Bilirubin, mg/dL 0.97 ± 0.34  
   Albumin, g/dL 3.17 ± 0.47  
   Aspartate transaminase, U/L 71 ± 33  
   Alanine transaminase, U/L 42 ± 11  
   Platelet, × 103/mL 187.5 ± 54.0  
Metastatic site(s)   
   Abdominal lymph node 18 62
   Lung 10 35
   Bone 11 38